Anebulo Pharmaceuticals Financials
ANEB Stock | USD 1.59 0.03 1.85% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 14.71 | 15.48 |
|
|
Investors should never underestimate Anebulo Pharmaceuticals' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Anebulo Pharmaceuticals' cash flow, debt, and profitability to make informed and accurate decisions about investing in Anebulo Pharmaceuticals.
Net Income |
|
Anebulo | Select Account or Indicator |
Understanding current and past Anebulo Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Anebulo Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Anebulo Pharmaceuticals' assets may result in an increase in income on the income statement.
Please note, the presentation of Anebulo Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Anebulo Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Anebulo Pharmaceuticals' management manipulating its earnings.
Anebulo Pharmaceuticals Stock Summary
Anebulo Pharmaceuticals competes with Adagene, Acrivon Therapeutics,, AnaptysBio, Mineralys Therapeutics,, and Aerovate Therapeutics. Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. The company was incorporated in 2020 and is based in Lakeway, Texas. Anebulo Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US0345691036 |
CUSIP | 034569103 |
Location | Texas; U.S.A |
Business Address | 1017 Ranch Road |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.anebulo.com |
Phone | 512 598 0931 |
Currency | USD - US Dollar |
Anebulo Pharmaceuticals Key Financial Ratios
Return On Equity | -1.14 | ||||
EBITDA | (8.05 M) | ||||
Net Income | (8.2 M) | ||||
Cash Per Share | 0.62 X | ||||
Current Ratio | 30.40 X |
Anebulo Pharmaceuticals Key Balance Sheet Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Total Assets | 21.7M | 15.6M | 11.7M | 4.1M | 3.7M | 3.5M | |
Other Current Liab | 131.6K | 131.7K | 534.3K | 104.2K | 119.8K | 203.3K | |
Net Debt | (20.0M) | (14.5M) | (11.2M) | (3.1M) | (3.6M) | (3.7M) | |
Retained Earnings | (38.6M) | (45.5M) | (57.2M) | (65.4M) | (58.9M) | (61.8M) | |
Accounts Payable | 110.0K | 380.8K | 534.5K | 156.4K | 179.9K | 260.0K | |
Cash | 20.0M | 14.5M | 11.2M | 3.1M | 2.8M | 2.6M | |
Other Current Assets | 1.7M | 1.0M | 422.7K | 413.8K | 372.4K | 565.7K | |
Total Liab | 241.6K | 512.5K | 1.1M | 260.6K | 234.5K | 222.8K | |
Total Current Assets | 20.0M | 14.5M | 11.2M | 3.5M | 3.2M | 3.0M |
Anebulo Pharmaceuticals Key Income Statement Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Interest Income | 7.3K | 92.4K | 147.6K | 249.0K | 286.4K | 300.7K | |
Interest Expense | 11.8K | 7.3K | 0.0 | 151.2K | 173.9K | 182.6K | |
Operating Income | (3.6M) | (6.8M) | (11.8M) | (8.3M) | (7.5M) | (7.9M) | |
Ebit | (33.9M) | (6.8M) | (11.8M) | (8.3M) | (9.6M) | (10.0M) | |
Research Development | 2.3M | 3.0M | 5.6M | 3.5M | 4.1M | 3.2M | |
Ebitda | (30.2M) | 5.6K | (11.8M) | (8.1M) | (9.3M) | (9.7M) | |
Income Before Tax | (30.3M) | (6.8M) | (11.7M) | (8.2M) | (9.4M) | (9.9M) | |
Net Income | (30.3M) | (6.8M) | (11.7M) | (8.2M) | (9.4M) | (9.9M) |
Anebulo Pharmaceuticals Key Cash Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Change In Cash | 17.0M | (5.4M) | (3.3M) | (8.2M) | (7.3M) | (7.0M) | |
Free Cash Flow | (4.9M) | (5.4M) | (9.7M) | (8.1M) | (7.3M) | (7.6M) | |
Change In Working Capital | (1.4M) | 907.8K | 1.2M | (799.3K) | (919.1K) | (873.2K) | |
Other Cashflows From Financing Activities | (821.6K) | (317.1K) | (264.7K) | (62.4K) | (56.1K) | (53.3K) | |
Other Non Cash Items | 26.6M | 209.9K | 731.0K | 151.2K | 136.1K | 129.3K | |
Total Cash From Operating Activities | (4.9M) | (5.4M) | (9.7M) | (8.1M) | (7.3M) | (7.6M) | |
Net Income | (30.3M) | (6.8M) | (11.7M) | (8.2M) | (9.4M) | (9.9M) | |
End Period Cash Flow | 20.0M | 14.5M | 11.2M | 3.1M | 2.8M | 2.6M |
Anebulo Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Anebulo Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Anebulo Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Anebulo Pharmaceuticals competition to find correlations between indicators driving Anebulo Pharmaceuticals's intrinsic value. More Info.Anebulo Pharmaceuticals is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Anebulo Pharmaceuticals' Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Anebulo Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Anebulo Pharmaceuticals Systematic Risk
Anebulo Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Anebulo Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Anebulo Pharmaceuticals correlated with the market. If Beta is less than 0 Anebulo Pharmaceuticals generally moves in the opposite direction as compared to the market. If Anebulo Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Anebulo Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Anebulo Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Anebulo Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Anebulo Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Anebulo Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Anebulo Pharmaceuticals growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Anebulo Pharmaceuticals January 18, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Anebulo Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Anebulo Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Anebulo Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Anebulo Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Anebulo Pharmaceuticals's daily price indicators and compare them against related drivers.
Downside Deviation | 6.7 | |||
Information Ratio | 2.0E-4 | |||
Maximum Drawdown | 40.03 | |||
Value At Risk | (10.43) | |||
Potential Upside | 7.64 |
Complementary Tools for Anebulo Stock analysis
When running Anebulo Pharmaceuticals' price analysis, check to measure Anebulo Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Anebulo Pharmaceuticals is operating at the current time. Most of Anebulo Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Anebulo Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Anebulo Pharmaceuticals' price. Additionally, you may evaluate how the addition of Anebulo Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |